Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | DNA topoisomerase ii | 0.0549 | 0.1094 | 0.1981 |
Wolbachia endosymbiont of Brugia malayi | topoisomerase IA, TopA | 0.0232 | 0.0018 | 0.0018 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.078 | 0.1879 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.078 | 0.1879 | 1 |
Plasmodium vivax | DNA topoisomerase 3, putative | 0.0232 | 0.0018 | 0.0018 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.1833 | 0.5447 | 1 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.078 | 0.1879 | 0.1879 |
Brugia malayi | Probable DNA topoisomerase II | 0.078 | 0.1879 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.078 | 0.1879 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.2124 | 0.6432 | 0.6432 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.078 | 0.1879 | 1 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0549 | 0.1094 | 0.1981 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.078 | 0.1879 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0549 | 0.1094 | 0.1981 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.1809 | 0.5367 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0549 | 0.1094 | 0.1981 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.3176 | 1 | 1 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.3176 | 1 | 1 |
Plasmodium falciparum | DNA gyrase subunit B | 0.3176 | 1 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.1833 | 0.5447 | 1 |
Treponema pallidum | DNA topoisomerase I (topA) | 0.0232 | 0.0018 | 0.0018 |
Giardia lamblia | DNA topoisomerase II | 0.0679 | 0.1534 | 1 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.078 | 0.1879 | 1 |
Schistosoma mansoni | DNA topoisomerase II | 0.078 | 0.1879 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.1833 | 0.5447 | 1 |
Mycobacterium leprae | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.1053 | 0.2802 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.078 | 0.1879 | 1 |
Mycobacterium ulcerans | DNA topoisomerase I | 0.0232 | 0.0018 | 0.0018 |
Trypanosoma brucei | DNA topoisomerase ii | 0.1833 | 0.5447 | 1 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.078 | 0.1879 | 0.1879 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.3176 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0525 | 0.1014 | 0.5353 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.078 | 0.1879 | 0.35 |
Plasmodium falciparum | DNA topoisomerase 3, putative | 0.0232 | 0.0018 | 0.0018 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.078 | 0.1879 | 1 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.078 | 0.1879 | 1 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0232 | 0.0018 | 0.0034 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.078 | 0.1879 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0525 | 0.1014 | 0.5353 |
Toxoplasma gondii | DNA topoisomerase family protein | 0.0232 | 0.0018 | 0.0034 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.3176 | 1 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0232 | 0.0018 | 0.0018 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.3176 | 1 | 1 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0549 | 0.1094 | 0.1981 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 4 uM | Cytotoxicity against human MT2 cells by XTT assay | ChEMBL. | 23434230 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.